Sleep-Disordered Breathing

Sleep apnea is the most underdiagnosed cardiovascular risk factor in midlife — and one of the most cost-effective to fix. If you do nothing else after reading this site, screen yourself.

Obstructive sleep apnea (OSA) is one of the most underdiagnosed conditions in midlife. Estimated prevalence: ~30–40% in middle-aged men, 15–20% in middle-aged women — and the majority are undiagnosed. Untreated, it raises mortality, hypertension (especially resistant), atrial fibrillation, stroke, dementia, type 2 diabetes, and erectile dysfunction.

If you do nothing else after reading this site, screen yourself for OSA.

What OSA actually is

OSA is repetitive partial (hypopnea) or complete (apnea) collapse of the upper airway during sleep.^[1] Each event causes a brief drop in oxygen saturation, sympathetic surge, and a partial arousal that fragments sleep. People with severe OSA may have 30+ events per hour without remembering any of them.

A 2016 meta-analysis of 27 cohort studies (n>3 million) showed severe OSA was associated with HR 2.13 for all-cause mortality and HR 2.73 for cardiovascular mortality.^[2] A 2025 update in Diagnostics confirmed dose-response: HR 1.21 mild, 1.56 moderate, 2.45 severe OSA for incident CVD.^[3]

The Apnea-Hypopnea Index (AHI):

Normal: <5 events/hour
Mild: 5–14
Moderate: 15–29
Severe: ≥30

Who's at risk

Major risk factors:

Male sex (though women are dramatically underdiagnosed; postmenopausal women catch up)
BMI ≥30
Neck circumference (>43 cm men, >40 cm women)
Craniofacial anatomy: retrognathia, narrow palate, large tongue
Family history
Alcohol and sedative use
Hypothyroidism, acromegaly, PCOS

Symptoms (any of these warrants a workup):

Loud habitual snoring
Witnessed apneas, gasping/choking at night
Unrefreshing sleep, daytime sleepiness
Resistant hypertension (HTN that responds poorly to multiple drugs)
Atrial fibrillation
Morning headache
Erectile dysfunction
Nocturia (multiple wake-ups to urinate)

Screening tools

The STOP-Bang questionnaire is validated and free.^[4]

Snoring loud
Tired during day
Observed apneas
Pressure (HTN)
BMI >35
Age >50
Neck circumference large
Gender male

≥3 yes = high risk; refer for a sleep study.

Home sleep apnea testing (HSAT) is now the standard first-line study in most patients without significant comorbidities — accurate, cheap, no overnight lab visit. Polysomnography (PSG, in-lab) is reserved for complex cases.

Treatment: CPAP and alternatives

CPAP (continuous positive airway pressure) is first-line for moderate-severe OSA.

Adherence threshold: ≥4 hours/night, ≥70% of nights.
Adherence is the single biggest determinant of CPAP outcomes; ~30–50% of patients struggle. Modern auto-adjusting machines, well-fitted masks, humidification, and clinician follow-up dramatically improve adherence.
Hard outcomes: Adherent CPAP reduces blood pressure, improves daytime function, reduces motor vehicle accidents, and is associated with reduced AF recurrence and possibly cardiovascular events. The SAVE trial (2016) was negative on the primary CV endpoint, but adherence was poor (mean 3.3 h/night). Subsequent analyses adjusting for adherence are more favorable.

Alternatives for those who can't tolerate CPAP or have mild OSA:

Mandibular advancement devices (MADs) — custom-fitted oral appliances, modest efficacy for mild-moderate OSA, well-tolerated.
Positional therapy — for those whose OSA is supine-only.
Weight loss — every 10% BMI reduction associates with ~25% AHI reduction; bariatric surgery can cure OSA in obese patients.
Hypoglossal nerve stimulation (Inspire) — implanted device for selected patients, AHI reduction ~70% in responders.
Surgery — uvulopalatopharyngoplasty (UPPP) has variable efficacy; maxillomandibular advancement is more effective but invasive.
GLP-1 agonists — emerging evidence (SURMOUNT-OSA 2024) shows tirzepatide significantly reduces AHI in OSA + obesity.

Nasal vs. mouth breathing

Nasal breathing during sleep is the physiological default and is associated with:

More stable airflow and oxygenation
Better humidification and filtration
Slightly lower OSA severity in some studies (mouth breathing tends to collapse the airway further)
Higher nitric oxide delivery to the lungs (sinuses produce NO)

Mouth breathing during sleep often signals nasal obstruction (deviated septum, allergic rhinitis, polyps, turbinate hypertrophy) or anatomical predisposition. Treating the underlying obstruction (with appropriate ENT evaluation) often resolves it.

Mouth taping: the honest assessment

Mouth taping has become a viral sleep "biohack." The honest evidence summary:

Clinical evidence is mixed and limited. A few small studies in mild OSA suggest modest AHI reduction with chin straps or mouth tape; others show no benefit.
Real risks if undertaken without clinical evaluation:
- Asphyxiation if there is undiagnosed nasal obstruction
- Worsening of OSA in patients who are obligate mouth breathers due to airway anatomy
- Aspiration risk if vomiting occurs
- Skin irritation from adhesive
The 2024 American Academy of Sleep Medicine commentary explicitly warned against unsupervised mouth taping.

What to do instead if you suspect mouth breathing:

See your physician for evaluation of nasal obstruction (allergic rhinitis, deviated septum, turbinate hypertrophy, polyps).
Get screened for OSA if you snore or have any cardiometabolic risk factor.
Treat allergic rhinitis (intranasal corticosteroids, antihistamines).
Try side sleeping, which reduces both snoring and AHI.
Consider a structural evaluation with an ENT or dentist trained in airway-focused care if anatomy is the issue.
If a clinician advises it after evaluation, mouth taping may be appropriate — but it is not a self-prescribed first-line intervention.

The oral-systemic axis

OSA, periodontal disease, and systemic inflammation share bidirectional links. Treating periodontal disease lowers systemic CRP and IL-6 — with intensive non-surgical periodontal therapy reducing hs-CRP at an effect size comparable to intensive lifestyle or statin therapy. Severe periodontitis is itself associated with elevated cardiovascular risk, and P. gingivalis gingipains are now detectable in Alzheimer's brain tissue. Oral health is part of brain and cardiovascular health, not separate from it — see Oral health.